Immunology
The Immunology Department at St James’s hospital runs a number of both investigator-led and industry centered drug trials in Immunology.
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| HAE Survey | Burden of hereditary angioedema (HAE) and impact on quality of life: A multi-national survey of patients and caregivers | Observational-non invasive | Takeda | Commercial: Industry |
| Intercept | A Phase 2, Double- Blind Randomized, Parallel- Group Study Evaluating the Efficacy, Safety and Tolerability of Obeticholic Acid, Administrated Alone or in Combination with Bezafibrate, in subjests with Primary Biliary Cholangitis who had an Inadequate Response or who were Unable to Tolerate Ursodeoxycholic Acid | Clinical trial NCT04594694) | Intercept Pharmaceutials | Commercial: Industry |
| HyQvia | Non-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQvia | Observational-non invasive (NCT01034969) | Baxalta | Commercial: Industry |
| IOS registry | Icatibant Outcome Survey (IOS) registry protocol | Observational-non invasive (NCT01034969) | Shire | Commercial: Industry |
| ABT in Urticaria | Health through attention based training (ABT) for patients in SJH with urticaria | Observational-non invasive | Non-commercial: Academic | |
| SOLAR study | A Phase IIIb, Randomized, Multicenter, Active-controlled,Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed | Clinical trial | ViiV Healthcare | Commercial: Industry |
| Santorini | Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI) | Observational-non invasive | Daiichi Sankyo Europe GmbH | Commercial: Industry |
| Study Name | Study Title | Study Type | Sponsor | Sponsor Type |
|---|---|---|---|---|
| CDZ OLE | An open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | Clinical Trial (NCT02859727)(2016-000468-41) | Novartis | Commercial: Industry |
| CDZ | An open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) | Clinical Trial (NCT02435173) (2014-003876-22) | Novartis | Commercial: Industry |